|
|
| | Bunamiodyl Basic information |
| Product Name: | Bunamiodyl | | Synonyms: | Bunamiodyl;buniodyl;2-[[2,4,6-Triiodo-3-[(1-oxobutyl)amino]phenyl]methylene]butanoic acid;2-(3-Butyramido-3,4,6-triiodophenylmethylene)butyric acid;3-(3-Butylamido-2,4,6-triiodphenyl)-2-ethylacrylsaeure;Bunamijodylum;Bunamiodilo;Bunamiodilo [inn-spanish] | | CAS: | 1233-53-0 | | MF: | C15H16I3NO3 | | MW: | 639.01 | | EINECS: | | | Product Categories: | | | Mol File: | 1233-53-0.mol |  |
| | Bunamiodyl Chemical Properties |
| Melting point | 105-120 °C | | Boiling point | 623.0±55.0 °C(Predicted) | | density | 2.202±0.06 g/cm3(Predicted) | | pka | 4.39±0.23(Predicted) |
| | Bunamiodyl Usage And Synthesis |
| Definition | ChEBI: Bunamiodyl is a member of cinnamic acids. | | Brand name | Bunaiod;Orabilex;Orabilix. | | World Health Organization (WHO) | Bunamiodyl, an orally administered radio-opaque medium, was
introduced in 1958 for use in the examination of the biliary tract. By 1964 its use
had been associated with cases of renal failure, in some cases fatal, which resulted
in its withdrawal by the United States Food and Drug Administration. Buniamiodyl
was withdrawn worldwide by the manufacturer in 1984. |
| | Bunamiodyl Preparation Products And Raw materials |
|